News

Long seen as a cost center by healthcare administrators, infection prevention programs have taken a beating when hospital budgets are cut. Infection preventionists are fighting back by making the business case for their programs to fend off additional cost-cutting as well as to demonstrate return on investment (ROI). While infection prevention has always been about patient and healthcare worker safety, it increasingly must show economic dividends -- it's a departure from the purely clinical path that infection preventionists have always taken, but essential for the future viability.

A new whitepaper is available to assist medical device manufacturers with understanding recent changes to the Food and Drug Administration (FDA)'s thinking regarding endotoxin testing.